Fibrocell Science reports plans to conduct public sale of common stock

Bookrunner Wells Fargo and co-managers Roth Capital and Griffin assist

By Devika Patel

Knoxville, Tenn., July 21 – Fibrocell Science, Inc. said it plans to price a public offering of common stock.

Wells Fargo Securities, LLC is the bookrunner, Roth Capital Partners and Griffin Securities are the co-managers.

Proceeds will be used for clinical and preclinical development and general corporate purposes.

Fibrocell is a biotechnology company based in Exton, Pa.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.